Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

NK Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01823198
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:29.409250+00:00
Published At
2023-11-07T00:00:00+00:00
Record Updated At
2023-11-07
Results Posted At
2023-11-07
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Acute Erythroid Leukemia", "Acute Megakaryoblastic Leukemia", "Acute Myeloid Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Acute Myeloid Leukemia in Remission", "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Blasts Under 20 Percent of Bone Marrow Nucleated Cells", "Blasts Under 20 Percent of Peripheral Blood White Cells", "Chronic Myelomonocytic Leukemia", "High Risk Myelodysplastic Syndrome", "Myelodysplastic Syndrome", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Therapy-Related Acute Myeloid Leukemia", "Therapy-Related Myelodysplastic Syndrome"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-11-07"
protocolSection.identificationModule.nctId
"NCT01823198"
protocolSection.identificationModule.officialTitle
"NK Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2023-11-07"

Study condition terms

  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (protocolSection.conditionsModule.conditions)
  • Acute Erythroid Leukemia (protocolSection.conditionsModule.conditions)
  • Acute Megakaryoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
  • Acute Myeloid Leukemia in Remission (protocolSection.conditionsModule.conditions)
  • Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (protocolSection.conditionsModule.conditions)
  • Blasts Under 20 Percent of Bone Marrow Nucleated Cells (protocolSection.conditionsModule.conditions)
  • Blasts Under 20 Percent of Peripheral Blood White Cells (protocolSection.conditionsModule.conditions)
  • Chronic Myelomonocytic Leukemia (protocolSection.conditionsModule.conditions)
  • High Risk Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
  • Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
  • Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive (protocolSection.conditionsModule.conditions)
  • Therapy-Related Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Therapy-Related Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.